Jose E Martínez-Rodríguez1, Alvaro Cobo-Calvo2, Luisa M Villar3, Elvira Munteis4, Yolanda Blanco5, Raquel Rasal4, Andrea Vera6, Aura Muntasell7, Roberto Alvarez-Lafuente8, Albert Saiz5, Jose C Alvarez-Cermeño9, Sergio Martínez-Yélamos2, Jaume Roquer4, Miguel López-Botet10. 1. Neurology Department, Hospital del Mar Medical Research Institute, Spain JMartinezR@hospitaldelmar.cat. 2. Multiple Sclerosis Unit, University Hospital de Bellvitge, Spain. 3. Immunology Department, Hospital Universitario Ramón y Cajal, Spain. 4. Neurology Department, Hospital del Mar Medical Research Institute, Spain. 5. Neurology Service, Hospital Clinic and Institut d'Investigació August Pi I Sunyer, Spain. 6. Immunology Unit, University Pompeu Fabra, Spain. 7. Hospital del Mar Medical Research Institute, Spain. 8. Neurology Service, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Spain. 9. Neurology Department, Ramon y Cajal University Hospital, Spain. 10. Immunology Unit, University Pompeu Fabra, Spain/ Hospital del Mar Medical Research Institute, Spain.
Abstract
BACKGROUND: Human cytomegalovirus (HCMV) causes a highly prevalent infection which may have a multifaceted impact on chronic inflammatory disorders. However, its potential influence in multiple sclerosis (MS) remains controversial. The HCMV-host interaction may induce an adaptive reconfiguration of the natural killer (NK) cell compartment, whose hallmark is a persistent expansion of peripheral NKG2C+ NK-cells. OBJECTIVE: The purpose of this study was to evaluate whether the HCMV-driven NKG2C+ NK-cell expansion is related to the MS clinical course. METHODS: Multicentre analysis of NKG2C expression and genotype according to HCMV serostatus and time of assignment of irreversible disability scores in 246 MS patients prospectively followed up in our institutions. RESULTS: NKG2C expression was unrelated to disease-modifying drugs, remained stable under steady-state conditions, and was higher in HCMV(+) NKG2C(+/+) homozygous individuals. NKG2C+ NK-cell expansion in HCMV(+) patients, as compared to HCMV(+) or HCMV(-) patients with lower NKG2C+ NK-cells proportions, conferred a lower risk of progression in Cox regression analysis (Expanded Disability Status Scale (EDSS)>3.0, hazard ratio (HR)=0.33, 95% confidence interval (CI) 0.15-0.71, p=0.005; EDSS>5.5, HR=0.23, 95% CI 0.07-0.74, p=0.014). Neither HCMV serostatus nor NKG2C genotype appeared to be related to disability progression. CONCLUSIONS: HCMV may exert a beneficial influence on MS, decreasing the risk of disability progression in those patients displaying a virus-driven NKG2C+ NK-cell expansion.
BACKGROUND:Human cytomegalovirus (HCMV) causes a highly prevalent infection which may have a multifaceted impact on chronic inflammatory disorders. However, its potential influence in multiple sclerosis (MS) remains controversial. The HCMV-host interaction may induce an adaptive reconfiguration of the natural killer (NK) cell compartment, whose hallmark is a persistent expansion of peripheral NKG2C+ NK-cells. OBJECTIVE: The purpose of this study was to evaluate whether the HCMV-driven NKG2C+ NK-cell expansion is related to the MS clinical course. METHODS: Multicentre analysis of NKG2C expression and genotype according to HCMV serostatus and time of assignment of irreversible disability scores in 246 MS patients prospectively followed up in our institutions. RESULTS:NKG2C expression was unrelated to disease-modifying drugs, remained stable under steady-state conditions, and was higher in HCMV(+) NKG2C(+/+) homozygous individuals. NKG2C+ NK-cell expansion in HCMV(+) patients, as compared to HCMV(+) or HCMV(-) patients with lower NKG2C+ NK-cells proportions, conferred a lower risk of progression in Cox regression analysis (Expanded Disability Status Scale (EDSS)>3.0, hazard ratio (HR)=0.33, 95% confidence interval (CI) 0.15-0.71, p=0.005; EDSS>5.5, HR=0.23, 95% CI 0.07-0.74, p=0.014). Neither HCMV serostatus nor NKG2C genotype appeared to be related to disability progression. CONCLUSIONS:HCMV may exert a beneficial influence on MS, decreasing the risk of disability progression in those patients displaying a virus-driven NKG2C+ NK-cell expansion.
Authors: Catharina C Gross; Andreas Schulte-Mecklenbeck; Heinz Wiendl; Emanuela Marcenaro; Nicole Kerlero de Rosbo; Antonio Uccelli; Alice Laroni Journal: Front Immunol Date: 2016-12-19 Impact factor: 7.561
Authors: Ana Zabalza; Andrea Vera; Elisenda Alari-Pahissa; Elvira Munteis; Antía Moreira; Jose Yélamos; Mireia Llop; Miguel López-Botet; Jose E Martínez-Rodríguez Journal: J Neuroinflammation Date: 2020-05-20 Impact factor: 8.322
Authors: Antía Moreira; Elisenda Alari-Pahissa; Elvira Munteis; Andrea Vera; Ana Zabalza; Mireia Llop; Noelia Villarrubia; Marcel Costa-García; Roberto Álvarez-Lafuente; Luisa María Villar; Miguel López-Botet; Jose E Martínez-Rodríguez Journal: Front Immunol Date: 2019-10-15 Impact factor: 7.561
Authors: Thanmayi Ranganath; Laura J Simpson; Anne-Maud Ferreira; Christof Seiler; Elena Vendrame; Nancy Zhao; Jason D Fontenot; Susan Holmes; Catherine A Blish Journal: Front Immunol Date: 2020-04-24 Impact factor: 7.561